Hsu-Ping Kuo

552 total citations
10 papers, 409 citations indexed

About

Hsu-Ping Kuo is a scholar working on Genetics, Pathology and Forensic Medicine and Immunology. According to data from OpenAlex, Hsu-Ping Kuo has authored 10 papers receiving a total of 409 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Genetics, 6 papers in Pathology and Forensic Medicine and 5 papers in Immunology. Recurrent topics in Hsu-Ping Kuo's work include Chronic Lymphocytic Leukemia Research (6 papers), Lymphoma Diagnosis and Treatment (4 papers) and Cancer Mechanisms and Therapy (2 papers). Hsu-Ping Kuo is often cited by papers focused on Chronic Lymphocytic Leukemia Research (6 papers), Lymphoma Diagnosis and Treatment (4 papers) and Cancer Mechanisms and Therapy (2 papers). Hsu-Ping Kuo collaborates with scholars based in United States, Belgium and Taiwan. Hsu-Ping Kuo's co-authors include Yee Chao, Kwan‐Hwa Chi, Shih‐Jen Liu, Chung‐Pin Li, Yu‐Shan Wang, Mint Sirisawad, Betty Chang, Masayuki Iwasaki, Dominik Schneidawind and Leo W.K. Cheung and has published in prestigious journals such as Blood, Cancer Cell and Cancer Research.

In The Last Decade

Hsu-Ping Kuo

10 papers receiving 407 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Hsu-Ping Kuo United States	8	186	174	150	123	72	10	409
Isabel Romero-Camarero Spain	7	172 0.9×	191 1.1×	88 0.6×	175 1.4×	73 1.0×	11	412
Zsolt Zoltán Fülöp Romania	9	87 0.5×	121 0.7×	142 0.9×	103 0.8×	85 1.2×	17	326
Noelia Purroy Spain	10	88 0.5×	113 0.6×	123 0.8×	136 1.1×	159 2.2×	18	334
Jenny Bulgarelli Italy	10	98 0.5×	153 0.9×	167 1.1×	78 0.6×	178 2.5×	20	389
Bertrand Montpellier France	6	143 0.8×	209 1.2×	163 1.1×	144 1.2×	103 1.4×	9	506
Kirsty Wienand United States	7	233 1.3×	93 0.5×	192 1.3×	238 1.9×	87 1.2×	15	399
Cristiana Di Bello Italy	9	93 0.5×	133 0.8×	141 0.9×	72 0.6×	133 1.8×	11	323
Alberto J. Arribas Switzerland	11	133 0.7×	185 1.1×	91 0.6×	220 1.8×	136 1.9×	50	430
E. Jane Leonard United States	10	206 1.1×	166 1.0×	69 0.5×	116 0.9×	77 1.1×	24	415
Irina Idler Germany	6	121 0.7×	143 0.8×	73 0.5×	123 1.0×	123 1.7×	8	311

Countries citing papers authored by Hsu-Ping Kuo

Since Specialization

Citations

This map shows the geographic impact of Hsu-Ping Kuo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hsu-Ping Kuo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hsu-Ping Kuo more than expected).

Fields of papers citing papers by Hsu-Ping Kuo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hsu-Ping Kuo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hsu-Ping Kuo. The network helps show where Hsu-Ping Kuo may publish in the future.

Co-authorship network of co-authors of Hsu-Ping Kuo

This figure shows the co-authorship network connecting the top 25 collaborators of Hsu-Ping Kuo. A scholar is included among the top collaborators of Hsu-Ping Kuo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hsu-Ping Kuo. Hsu-Ping Kuo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

Vu, John P., Chen‐Yen Yang, Mint Sirisawad, et al.. (2021). Glutamate-cysteine ligase catalytic subunit as a therapeutic target in acute myeloid leukemia and solid tumors.. American Journal of Cancer Research. 11(6). 2911–2927. 7 indexed citations

Kuo, Hsu-Ping, Scott A. Ezell, Karl J. Schweighofer, et al.. (2017). Combination of Ibrutinib and ABT-199 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma. Molecular Cancer Therapeutics. 16(7). 1246–1256. 45 indexed citations

Kuo, Hsu-Ping, et al.. (2016). Ibrutinib Potentiated NK Cell-Mediated Cytotoxicity in Mouse Models of B-Cell Lymphomas. Blood. 128(22). 4140–4140. 2 indexed citations

Huang, Yujun, Jeff Hsu, Mint Sirisawad, Hsu-Ping Kuo, & Betty Chang. (2016). Abstract 4860: The BTK inhibitor ibrutinib modulates T cell immunity in mouse models and in differentiated human T cells. Cancer Research. 76(14_Supplement). 4860–4860. 1 indexed citations

Kuo, Hsu-Ping, Scott A. Ezell, Karl J. Schweighofer, et al.. (2016). The role of PIM1 in the ibrutinib-resistant ABC subtype of diffuse large B-cell lymphoma.. PubMed. 6(11). 2489–2501. 37 indexed citations

Wong, Stephen H.K., David L. Goode, Masayuki Iwasaki, et al.. (2015). The H3K4-Methyl Epigenome Regulates Leukemia Stem Cell Oncogenic Potential. Cancer Cell. 28(2). 198–209. 103 indexed citations

Kuo, Hsu-Ping, Karl J. Schweighofer, Leo W.K. Cheung, et al.. (2015). The Role of PIM1 in the Ibrutinib-Resistant ABC Subtype of Diffuse Large B-Cell Lymphoma. Blood. 126(23). 699–699. 39 indexed citations

Kuo, Hsu-Ping, R. Webster Crowley, Ling Xue, et al.. (2014). Combination of Ibrutinib and BCL-2 or SYK Inhibitors in Ibrutinib Resistant ABC-Subtype of Diffuse Large B-Cell Lymphoma. Blood. 124(21). 505–505. 7 indexed citations

Chou, Chao‐Kai, Dung‐Fang Lee, Hui-Lung Sun, et al.. (2009). The suppression of MAD1 by AKT‐mediated phosphorylation activates MAD1 target genes transcription. Molecular Carcinogenesis. 48(11). 1048–1058. 17 indexed citations

10.

Chi, Kwan‐Hwa, Shih‐Jen Liu, Chung‐Pin Li, et al.. (2005). Combination of Conformal Radiotherapy and Intratumoral Injection of Adoptive Dendritic Cell Immunotherapy in Refractory Hepatoma. Journal of Immunotherapy. 28(2). 129–135. 151 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact